Colin A. Forestal Ph.D.

Dr. Colin Forestal has extensive experience working on intellectual property matters, with a focus on life sciences. Colin's diverse practice includes obtaining and evaluating domestic and foreign patent rights in the biotechnology, pharmaceutical, and diagnostic fields. He also regularly participates in patent due diligence and freedom-to-operate investigations across various technologies. In addition, he handles opinion work, participates in opposition proceedings before the European Patent Office, and is experienced in handling licensing disputes.

Colin works on a wide range of technologies, including cell-based therapies, antisense therapeutics, protein glycosylation, molecular diagnostics, enzyme replacement therapies, viruses, antiviral drugs, and vaccine development. He also has extensive knowledge regarding antibodies, including patent prosecution strategies relating to them. Specifically, Colin has developed patent strategies for Celgene Cellular Therapeutics' stem cell therapeutics, GlycoVaxyn AG's next-generation bioconjugate vaccines, and therapeutic antibodies developed by Genentech, Inc. [1]